SA
GNNSF logo
Genscript Biotech Corporation(GNNSF)
Closing price · checked 10:35 PM ETAbout this dataData status
$3.53▼-0.25 (-6.61%)
Extended:$3.78+0.25 (+7.08%)· 10:35 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Genscript Biotech Corporation (GNNSF)

EBITDA

$600.31M

TTM · Period ending: · USD

GNNSF logo

GNNSF EBITDA

Latest reported$600.31M
GNNSF EBITDA ($13.08M → $600.31M)
Powered by
High-resolution chart · PNG

What is ebitda?

EBITDA is earnings before interest, taxes, depreciation and amortization. It is a measure of earnings, not cash flow.

Compare ebitda

GNNSF ebitda history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

Genscript Biotech Corporation EBITDA — Annual fiscal periods (USD)
Period endingEBITDA (USD)Change
329,662,582+363.85%
71,071,385—
-249,423,000—
-354,173,000—
-465,512,174—
-171,651,000—
-92,586,155−359.45%
35,686,000−21.61%
45,521,000+20.08%
37,909,000+94.47%
19,493,000+48.26%
13,148,000+0.49%
13,084,000—

Frequently asked questions: GNNSF ebitda

What is Genscript Biotech Corporation (GNNSF)'s current ebitda?

Genscript Biotech Corporation (GNNSF)'s latest reported ebitda (TTM) is $600.31M as of Jun 30, 2026. EBITDA is earnings before interest, taxes, depreciation and amortization. It is a measure of earnings, not cash flow.

How much historical ebitda data is available for GNNSF?

Stock Alarm Pro provides 13 dated annual fiscal periods observations for Genscript Biotech Corporation (GNNSF)'s ebitda, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare GNNSF's ebitda to peers or set an alert?

You can compare GNNSF's ebitda directly against sector peers (LLY, JNJ, ABBV, MRK) on Stock Alarm Pro, open the multi-ticker series in Chart Studio, or set real-time price and valuation alerts on GNNSF delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.